Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14031180 | 0.90 | HRH2 (0.40) | ALDH1A1LMNATP53EPHX2GAA | |
| SCHEMBL459515 | 0.88 | EPHX2 (0.40) | ALDH1A1LMNATP53EPHX2KDM4E | |
| SCHEMBL14291373 | 0.85 | ALDH1A1 (0.32) | ALDH1A1LMNATP53EPHX2GAA | |
| SCHEMBL371418 | 0.83 | ALDH1A1 (0.40) | ALDH1A1LMNATP53EPHX2SMN1; SMN2 | |
| SCHEMBL10035940 | 0.80 | IDO1 (0.39) | ALDH1A1LMNATP53EPHX2KDM4E | |
| SCHEMBL10035886 | 0.77 | POLB (0.35) | ALDH1A1LMNATP53EPHX2GAA | |
| SCHEMBL5842509 | 0.77 | KDM4E (0.38) | ALDH1A1LMNATP53EPHX2SMN1; SMN2 | |
| SCHEMBL5841590 | 0.77 | ALDH1A1 (0.34) | ALDH1A1LMNATP53EPHX2KDM4E | |
| SCHEMBL5842513 | 0.77 | KDM4E (0.38) | ALDH1A1LMNATP53EPHX2SMN1; SMN2 | |
| SCHEMBL3508536 | 0.76 | TDP1 (0.36) | ALDH1A1LMNATP53EPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130142739-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | AURIGA INTERNATIONAL (BE) | 2013-06-06 | — | — | US | disclosed |
| US-20130142739-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | AURIGA INTERNATIONAL (BE) | 2013-06-06 | — | — | US | disclosed |
| US-20130142739-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | AURIGA INTERNATIONAL (BE) | 2013-06-06 | — | — | US | disclosed |
| WO-2012010644-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | AURIGA INTERNATIONAL (BE) | 2012-01-26 | — | — | WO | disclosed |
| EP-2409693-A2 | Isothiocyanates and derivatives for use in the treatment and / or prevention of polymorphous light eruptions | Auriga International (BE) | 2012-01-25 | — | — | EP | disclosed |
| EP-2409693-A2 | Isothiocyanates and derivatives for use in the treatment and / or prevention of polymorphous light eruptions | Auriga International (BE) | 2012-01-25 | — | — | EP | disclosed |
| WO-2008015315-A1 | THIOUREA-CONTAINING MEDICINAL COMPOUNDS FOR TREATING CANCER IN ASSOCIATION WITH CHEMOTHERAPUTIC AGENTS OR IONIZING OR NON-IONIZING RADIATION | LMD (FR) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142739-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | TST, CBS, SRM | ALDH1A1 1586/4885LMNA 4543/4885TP53 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.